The Development of Vitamin D-Based Therapies for Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 4, 2004, Pages 202-205

  Price, Nancy ^a   D'Orazio, Amy ^a   Jain, Vinay K ^a   Sartor, Oliver ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DN 101; DOCETAXEL; MITOXANTRONE; PACLITAXEL; UNCLASSIFIED DRUG; VITAMIN D;

CALCIUM INTAKE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERCORTISOLISM; INHIBITION KINETICS; MAXIMUM TOLERATED DOSE; PREMEDICATION; PROSTATE CARCINOMA; REVIEW; SIDE EFFECT;

EID: 16544372395     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70044-0     Document Type: Article

References (26)

1. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13:325-349.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10:1307-1311.
3. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2:467-472.
4. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002; 1:667-677.
5. Kobayashi T, Hashimoto K, Yoshikawa K. Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 1993; 196:487-493.
6. Liu M, Lee MH, Cohen M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10:142-153.
7. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271:1861-1864.
8. Majewski S, Szmurlo A, Marczak M, et al. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett 1993; 75:35-39.
9. Mantell DJ, Owens PE, Bundred NJ, et al. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87:214-220.
10. Park WH, Seol JG, Kim ES, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000; 109:576-583.
11. Tang W, Ziboh VA, Isseroff RR, et al. Novel regulatory actions of 1 alpha,25-dihydroxyvitamin D3 on the metabolism of polyphosphoinositides in murine epidermal keratinocytes. J Cell Physiol 1987; 132:131-136.
12. Haugen JD, Pittelkow MR, Zinsmeister AR, et al. 1 alpha,25-dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor beta 2 release. Biochem Biophys Res Commun 1996; 229:618-623.
13. Hershberger PA, Yu WD, Modzelewski RA, et al. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001; 7:1043-1051.
14. Hershberger PA, McGuire TF, Yu WD, et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 2002; 1:821-829.
15. Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999; 5:695-703.
16. Ahmed S, Johnson CS, Rueger RM, et al. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 2002; 168:756-761.
17. Gross C, Stamey T, Hancock S, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159:2035-2039.
18. Osborn JLS, Smith GG, Bahnson DC, et al. Phase II trial of oral 1, 24-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995; 1:195-198.
19. Trump DL, Serafine A, Brufsky J, et al. High dose calcitriol (1, 25 (OH) 2 vitamin D3) + doxamethasone in androgen independent prostate cancer (AIPC). Proc Amer Soc Clin Oncol 2000; 19:337a (Abstract# 1327).
20. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001; 91:2431-2439.
21. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21:123-128.
22. Smith DC, Johnson CS, Freeman CC, et al. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999; 5:1339-1345.
23. Beer TM, Lemmon D, Lowe BA, et al. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003; 97:1217-1224.
24. Light BW, Yu WD, McElwain MC, et al. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997; 57:3759-3764.
25. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002; 72:648-659.
26. Beer TM, Javle MM, Whitehouse MJ, et al. Phase I study and pharmacokinetic (PK) evaluation of DN-101, a new formulation of calcitriol. Proc Amer Soc Clin Oncol 2003; 22:231 (Abstract #924).